Cultural upbringing gives context to sexual dysfunction but does not make the diagnosis, according to Sameena Rahman, MD, FACOG.
News|Articles|July 2, 2025
Q2 Recap: What's new in obstetrics and gynecology?
Author(s)Morgan Ebert
Fact checked by: Celeste Krewson, Assistant Editor
Take a quick look at everything you may have missed during Q2 of 2025, including the latest FDA approvals, top stories, and exclusive interviews.
Advertisement
Advertisement
As we close out the first half of 2025, the second quarter has delivered major advancements across cervical cancer screening, infectious disease management, and preventive women’s health.
Related to this article
Experts address COVID-19 vaccine myths, safety evidence, and how to frame the benefits of vaccination in pregnancy.
Experts look ahead to new maternal vaccines and how to counsel patients on receiving several in one pregnancy.
In September, the FDA accepted an extended duration sNDA for the IUD with a decision expected in Q2 2027.
Experts discuss common patient concerns about vaccination in pregnancy and strategies to improve uptake.
Experts discuss how obstetric and pediatric clinicians can coordinate to protect newborns.
Experts review ACOG's 2026-27 guidance and the RSV window extension for pregnant and postpartum patients.
On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.
Advertisement
Advertisement